Clinical observation on recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in solid tumor patients
- VernacularTitle:重组人血小板生成素治疗实体肿瘤患者化疗后血小板减少的临床观察
- Author:
Yan WEI
;
Jian CHEN
;
Zhoumin XU
- Publication Type:Journal Article
- Keywords:
recombinant human thrombopoietin;
thrombocytopenia;
chemotherapy
- From:China Oncology
2006;0(09):-
- CountryChina
- Language:Chinese
-
Abstract:
Background and purpose:Reduced peripheral blood platelet count is a common toxicity in patients with hematological malignancy after chemotherapy.The purpose of this study was to observe the eff icacy and safety of recombinant human thrombopoietin(rhTPO)in the treatment of thrombocytopenia induced by chemotherapy.Methods:A total of 25 patients with solid tumor,who developed thrombocytopenia induced by chemotherapy(PLT≤70?109/L) after the f irst cycle of chemotherapy(control group),was studied by self-cross control.6-24 h after the second cycle of chemotherapy(treatment group) with identical scheme of the f irst cycle chemotherapy,they were given subcutaneous injection of rhTPO 15 000 U/d for 7 to 14 consecutive days or until platelet count ≥100?109/L or the increasing count ≥50?109/L.Results:The mean platelet count of the patients after rhTPO treatment was higher at different time points of the treatment group than that of the control group.The minimal PLT count of the treatment group and the control group after chemotherapy were(80.3?39.30)?109/L and(34.7?21.2)?109/L(P0.05).The time of PLT count to recover was found to be more than 75?109/L and 100?109/L in treatment group after chemotherapy was(9.8?4.2)d and(12.8?3.6)d,compared to(19.1?4.5)d and(24.3?1.4)d(P
